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An international prospective cohort study evaluating 
major vascular complications among patients 
undergoing noncardiac surgery:  the VISION Pilot Study 
 
 
The VISION PIlOT STudy INVeSTIgaTOrS
 
AbStrAct 
Objectives: Among patients undergoing noncardiac surgery, our objectives were to: (1) determine the feasibility of 
undertaking a large international cohort study; (2) estimate the current incidence of major perioperative vascular 
events; (3) compare the observed event rates to the expected event rates according to the Revised Cardiac Risk Index 
(RCRI); and (4) provide an estimate of the proportion of myocardial infarctions without ischemic symptoms that may 
go undetected without perioperative troponin monitoring. 
Design: An international prospective cohort pilot study.
Participants: Patients undergoing noncardiac surgery who were > 45 years of age, receiving a general or regional an-
esthetic, and requiring hospital admission.
Measurements: Patients had a Roche fourth-generation Elecsys troponin T measurement collected 6 to 12 hours post-
operatively and on the first, second, and third days after surgery. Our primary outcome was major vascular events (a 
composite of vascular death [i.e., death from vascular causes], nonfatal myocardial infarction, nonfatal cardiac arrest, 
and nonfatal stroke) at 30 days after surgery. Our definition for perioperative myocardial infarction included: (1) an 
elevated troponin T measurement with at least one of the following defining features: ischemic symptoms, develop-
ment of pathologic Q waves, ischemic electrocardiogram changes, coronary artery intervention, or cardiac imaging 
evidence of myocardial infarction; or (2) autopsy findings of acute or healing myocardial infarction. 
results: We recruited 432 patients across 5 hospitals in Canada, China, Italy, Colombia, and Brazil. During the first 
30 days after surgery, 6.3% (99% confidence interval 3.9–10.0) of the patients suffered a major vascular event (10 vas-
cular deaths, 16 nonfatal myocardial infarctions, and 1 nonfatal stroke). The observed event rate was increased 6-fold 
compared with the event rate expected from the RCRI. Of the 18 patients who suffered a myocardial infarction, 12 
(66.7%) had no ischemic symptoms to suggest myocardial infarction. 
conclusions: This study suggests that major perioperative vascular events are common, that the RCRI underesti-
mates risk, and that monitoring troponins after surgery can assist physicians to avoid missing myocardial infarction. 
These results underscore the need for a large international prospective cohort study. 
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A
  nnually,  approximately  200  million  adults 
 worldwide undergo major noncardiac surgery.
1,2   
    Despite its benefits, noncardiac surgery is asso-
ciated with adverse vascular complications, including 
vascular death, nonfatal myocardial infarction, non-
fatal cardiac arrest, and nonfatal stroke.
2 The increase 
in the number of elderly patients undergoing surgery, 
the change in the invasiveness of some surgical inter-
ventions, and the limitations of previous research (e.g., 
dated information, focus on select high-risk groups, 
single-centre studies), highlight uncertainty about the 
current incidence of major vascular events among pa-
tients undergoing noncardiac surgery.
3 Accurate infor-
mation about major vascular events associated with 
noncardiac surgery is necessary to inform clinicians, 
administrators, and granting agencies about the re-
sources required to confront this problem.
Further, uncertainty exists regarding the optimal 
clinical risk estimation model for predicting major vas-
cular events in patients undergoing noncardiac surgery.
4 
Previous risk modelling studies were underpowered, 
and most studies were conducted in a single-centre uni-
versity hospital in North America.
3 It is also important 
to know whether established risk models provide accur-
ate risk prediction in countries throughout the world, as 
perioperative practices and outcomes may vary inter-
nationally. Accurate risk estimation is essential to fa-
cilitate informed patient and physician decision-making 
regarding the appropriateness of noncardiac surgery 
and to triage patients to the most appropriate care after 
surgery. 
There is evidence from a large international random-
ized controlled trial and from several small prospective 
cohort studies that suggest troponin measurements after 
surgery can help physicians avoid missing perioperative 
myocardial infarction.
5,6 If monitoring troponins after 
noncardiac surgery helps physicians to detect periopera-
tive myocardial infarction that would otherwise go un-
detected, troponin screening could facilitate appropriate 
and timely interventions.
We undertook a pilot study with the following object-
ives: (1) to determine the feasibility of conducting a large 
international prospective cohort study to address these un-
certainties; (2) to estimate the current incidence of major 
vascular events in patients undergoing noncardiac surgery; 
(3) to compare the observed event rates with the expected 
event rates according to the Revised Cardiac Risk Index 
(RCRI);
3 and (4) to provide an estimate of the proportion of 
perioperative myocardial infarctions that may go undetect-
ed without troponin monitoring after surgery. 
Methods
Study design and eligibility criteria. We conducted a 
prospective cohort study of patients undergoing noncar-
diac surgery. The Vascular events In noncardiac Surgery 
patIents cOhort evaluatioN (VISION) Pilot Study was 
conducted at 5 centres: the Hamilton Health Sciences 
McMaster University Medical Centre (Hamilton, Can-
ada), the Prince of Wales Hospital (Hong Kong, China), 
the Italian National Cancer Institute “Regina Elena” 
(Rome, Italy), the Hospital Universitario de Santander 
(Bucaramanga, Colombia), and the Hospital de Clinicas 
de Porto Alegre (Porto Alegre, Brazil). Three of these 
centres (China, Colombia, Brazil) were general surgical 
hospitals, one was a cancer hospital (Italy), and one was 
a site, within a general hospital, that focused on intra- 
abdominal and orthopedic surgery (Canada). The Re-
search Ethics Board at each site approved the protocol 
before patient recruitment. 
Patients were eligible if they underwent noncardiac 
surgery, were > 45 years of age, and received a general or 
regional anesthetic (plexus block, spinal, or epidural). We 
included patients who underwent surgery during the day 
or at night, on a weekday or weekend, or who underwent 
elective or urgent/emergent surgery. We excluded pa-
tients receiving only local or topical anesthesia, those not 
requiring at least an overnight hospital admission after 
surgery, patients previously enrolled in the VISION Pilot 
Study, and patients who did not consent to participate. 
Patient recruitment. Most patients gave informed 
consent for participation in the study prior to sur-
gery. Patients for whom we could not obtain consent 
preoperatively (e.g., some urgent/emergent and night 
surgical cases) were included if research personnel ob-
tained consent within the first 24 hours after their sur-
gery. Research personnel screened the daily patient list 
in the preoperative assessment clinic to identify eligible 
patients undergoing elective surgery. To identify eligible 
patients admitted through the emergency department 
and those who did not attend the preoperative assess-
ment clinic, research personnel screened daily surgical 
lists, surgical lists from the previous day, patient lists for 
surgical wards and intensive care units, and patients in 
the preoperative holding area. Research personnel ap-
proached patients who fulfilled the eligibility criteria (or 
their families) to obtain written informed consent. 
Data collection, monitoring, and follow-up. Research 
personnel interviewed and examined patients and re-
viewed their charts to obtain information on potential Open Medicine 2011;5(4)e195
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predictors of major perioperative vascular events, in-
cluding risk factors from the RCRI.
7 Patients had blood 
collected to measure a Roche fourth-generation Elecsys 
troponin T assay 6 to 12 hours postoperatively and on 
the first, second, and third days after surgery. The co-
efficient of variation is < 10% at 0.035 μg/L. Based upon 
guideline recommendations, we considered a troponin T 
value ≥ 0.04 μg per litre to be elevated. Patients enrolled 
between 12 and 24 hours after surgery had a troponin 
T drawn immediately and continued testing as outlined 
above. An electrocardiogram (ECG) was undertaken im-
mediately after an elevated troponin measurement was 
detected. If a troponin T measurement was elevated but 
the patient had no ECG changes or ischemic signs or 
symptoms to fulfill the diagnostic criteria for myocar-
dial infarction, then we recommended that the patient 
undergo an echocardiographic study. 
Research personnel followed patients throughout their 
hospital stay, clinically evaluating them and examining 
their medical records to ensure that caregivers followed 
study orders and to identify primary and secondary out-
comes. We contacted patients by phone at 30 days after 
surgery; if patients (or their families) indicated that they 
had experienced an outcome, we contacted their phys-
icians to obtain documentation. Data collection forms 
and supporting documentation were faxed or entered 
online from participating centres directly to the iData-
Fax Management System at the coordinating centre in 
McMaster University. 
Outcomes. Table 1 provides the outcome definitions. For 
our first objective (to determine the feasibility of con-
ducting a large international cohort study), our primary 
outcome was achieving > 95% follow-up. For our second 
and third objectives (to estimate the current incidence 
of major vascular events and to compare the observed 
event rates with the expected event rates according to the 
RCRI), our primary outcome was major vascular events 
Table 1:  Outcome defi  nitions
Outcome Defi  nition
Classi￿  cation of death Vascular death is defi  ned as any death with a vascular cause and includes those deaths that occurred after 
myocardial infarction, cardiac arrest, stroke, cardiac revascularization procedure (i.e., percutaneous coronary 
intervention [PCI] or coronary artery bypass graft [CABG] surgery), pulmonary embolus, or hemorrhage; and deaths 
with an unknown cause. Non-vascular death is defi  ned as any death with a clearly documented non-vascular cause 
(e.g. , trauma, infection, malignancy).  
Myocardial infarction The diagnosis requires either one of the following: 
1.  A typical rise of troponin or a typical fall of an elevated troponin detected at its peak post surgery in a patient 
without a documented alternative explanation for an elevated troponin (e.g., pulmonary embolism).  This 
criterion also required that 1or more of the following defi  ning features existed: 
a.  Ischemic signs or symptoms (i.e., chest, arm, or jaw discomfort; shortness of breath, pulmonary edema)
b.  Development of pathologic Q waves > 30 milliseconds in any 2 contiguous leads
c.  ECG changes indicative of ischemia (i.e., ST segment elevation [≥ 2 mm in leads V1, V2, or V3 and ≥ 1 mm in 
the other leads], ST segment depression [≥ 1 mm], or symmetric inversion of T waves ≥ 1 mm in at least 2 
contiguous leads)
d.  Coronary artery intervention (i.e., PCI or CABG surgery).
 e.  New or presumed new cardiac wall motion abnormality on echocardiography or new or presumed new fi  xed 
defect on radionuclide imaging
2.  Pathologic fi  ndings of an acute or healing myocardial infarction
Non-fatal cardiac arrest The diagnosis requires a successful resuscitation from either documented or presumed ventricular fi  brillation, 
sustained ventricular tachycardia, asystole, or pulseless electrical alternans.
Congestive heart failure The diagnosis requires both clinical (i.e., any of the following signs: elevated jugular venous pressure, respiratory 
rales, crepitations, or presence of S3) and radiographic evidence (e.g., vascular redistribution, interstitial pulmonary 
edema, or frank alveolar pulmonary edema).
Clinically important atrial 
￿  brillation
Atrial fi  brillation that results in angina, congestive heart failure, symptomatic hypotension, or that requires 
treatment with a rate-controlling drug, anti-arrhythmic drug, or electrical cardioversion. 
Hospital readmission for vascular 
reasons
Hospital readmission for congestive heart failure, ischemic symptoms with ST or T wave changes on an ECG, 
arrhythmia, or stroke. 
Stroke A new focal neurological defi  cit thought to be vascular in origin with signs and symptoms lasting more than 24 
hours.Open Medicine 2011;5(4)e196
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(a composite of vascular death, nonfatal myocardial in-
farction, nonfatal cardiac arrest, and nonfatal stroke) 
at 30 days after surgery. The original publication of the 
RCRI used a broad composite outcome of myocardial 
infarction, pulmonary edema, ventricular fibrillation or 
primary cardiac arrest, and complete heart block.
7 This 
initial broad composite outcome did not include death 
from cardiac causes.
7 A subsequent publication of the 
RCRI data focused on the composite outcome of death 
from cardiac causes, nonfatal myocardial infarction, and 
nonfatal cardiac arrest.
3 We used estimates from this 
subsequent publication as our expected event rates ac-
cording to the RCRI, as this more closely matched our 
composite outcome.
3 
Individual secondary outcomes for our second object-
ive included vascular mortality, myocardial infarction, 
cardiac arrest, stroke, congestive heart failure, new clin-
ically important atrial fibrillation, and hospital readmis-
sion for vascular reasons at 30 days after surgery. For 
our fourth objective (to provide an estimate of the pro-
portion of perioperative myocardial infarctions that may 
go undetected without perioperative troponin monitor-
ing), our primary outcome at 30 days after surgery was 
any myocardial infarction without ischemic symptoms. 
Two outcome adjudicators independently assessed all 
major vascular events without knowledge of the patient’s 
vascular risk factors. All disagreements were resolved 
through a consensus process that required the adjudica-
tors to discuss the reasoning behind their decisions. If 
disagreement persisted, a third adjudicator made a final 
decision.
Analysis. We used a Fisher’s exact test to compare the 
proportion of urgent or emergent patients who under-
went surgery on a weekend to the proportion who 
underwent surgery on a weekday. We determined the 
proportion of patients suffering a major vascular event 
and the associated 99% confidence interval. For all pa-
tients, we determined the expected number of major vas-
cular events according to the RCRI and calculated the 
ratio of the observed to the expected number of events 
and the associated 99% confidence interval. 
Ethical considerations. All patients or their families 
provided written informed consent. 
results
Patients were recruited over a 1- to 2-month period at 
each participating site. Sites joined the pilot study over a 
4-year period. The first site started recruiting patients on 
30 March 2005, and the last patient was recruited at the 
final site on 19 May 2009. We recruited 432 patients who 
met the eligibility criteria into the VISION Pilot Study, 17 
(3.9%) of whom consented during the first 24 hours after 
surgery. The patient flow chart for recruitment across all 
sites is shown in Figure 1. A comparison of the study log 
with operating room surgical records, and, where avail-
able, hospital computer systems, demonstrated that study 
personnel approached 85.0% of all potentially eligible pa-
tients. Missed patients were primarily elective patients who 
were rescheduled on short notice, elective patients with the 
same booking time as many other elective cases, and some 
urgent/emergent patients who underwent weekend surgery 
and were missed by the weekend study personnel. Forty-
eight patients refused to participate (10.0% refusal rate). 
Table 2 presents the patient characteristics. Seventy-
one patients (16.4%) underwent surgery within 72 
hours of an acute event (i.e., urgent/emergent surgery). 
Of the 19 patients who underwent surgery on a week-
end, 12 (63.2%) met our definition for urgent/emergent 
surgery, whereas 59 (14.3%) of the 413 patients who 
underwent surgery on a weekday were in this category 
(p < 0.001). Sixty-one (14.1%) patients had a history of 
coronary artery disease, and 184 (42.6%) had a history 
of hypertension. 
The anesthesia received by patients included the fol-
lowing types: general, 369 patients (85.4%); spinal, 55 
patients (12.7%); thoracic epidural, 35 patients (8.1%); 
lumbar epidural, 12 patients(2.8%); and nerve block, 12 
patients (2.8%). Some patients received more than 1 type 
of anaesthesia. Patients underwent surgery for a median 
of 105 minutes (interquartile range [IQR] 70–165).
Three patients withdrew from the study, and we com-
pleted our 30-day follow-up on the remaining 429 (i.e., 
Eligible patients
n = 565
Patients approached 
to participate
n = 480
Patients included 
in the VISION Pilot Study
n = 432
Potentially eligible 
patients missed by 
research personnel
n = 85
Declined to participate
n = 48
Figure 1:  Patient flow chartOpen Medicine 2011;5(4)e197
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99.3% of patients completed follow-up). The median 
length of hospital stay was 5.5 days (IQR 3.0–10.0). Dur-
ing the first 30 days after surgery, 6.3% (99% CI 3.9–10.0) 
of the patients suffered a major vascular event (10 vas-
cular deaths, 16 nonfatal myocardial infarctions, and 1 
nonfatal stroke). Secondary outcomes included 10 (2.3%) 
patients who died of vascular causes, 18 (4.2%) patients 
who developed a myocardial infarction (16 nonfatal, 2 
fatal), 2 (0.5%) patients who had a stroke (1 nonfatal and 
1 fatal), 4 (0.9%) patients who developed congestive heart 
failure, 7 (1.6%) patients who developed new clinically 
important atrial fibrillation, and 1 (0.2%) patient who 
was readmitted to hospital for vascular reasons within 
30 days after surgery. Among urgent/emergent surgery 
patients, 8 (11.3%, 99% CI 3.7–24.3) suffered a major 
vascular event, and 5 (7.0%, 99% CI 1.6—18.7) suffered 
a myocardial infarction within 30 days after surgery. 
Among elective surgery patients 19 (5.3%, 99% CI 2.7–
9.1) suffered a major vascular event, and 13 (3.6%, 99% 
CI 1.6–7.0) suffered a myocardial infarction within 30 
days after surgery. 
Among the 18 patients who suffered a perioperative 
myocardial infarction, all had an elevated troponin T 
measurement and 1 or more of the following defining 
features: 6 (33.3%) had ischemic signs or symptoms, 3 
(16.6%) developed ST segment elevation, 5 (27.8%) de-
veloped ST segment depression, 9 (50.0%) developed T 
wave inversions, 1 (5.6%) underwent a coronary artery 
intervention, and 5 (27.8%) had a new or presumed new 
cardiac wall motion abnormality on echocardiography. 
All of the patients who suffered a myocardial infarc-
tion and had a new or presumed new wall motion ab-
normality on echocardiography also had ischemic ECG 
changes. 
Table 2:  Patient characteristics
Characteristics
Canada
(n = 99)
Colombia
(n = 50)
Italy
(n = 101)
Hong Kong
(n = 111)
Brazil
(n = 71)
Total
(n = 432)
Mean age, years (SD)  64  (11) 65 (13) 64 (100 64 (13) 61 (8) 63 (11)
Female sex, n (%) 60 (60.6) 26 (52.0) 50 (49.5) 54 (48.6) 39 (54.9) 229 (53.0)
Type of surgery
 Orthopedics
 Intra-abdominal
 Neurosurgery 
 Urology/Gynecology
  Head & Neck surgery
 Thoracic
 Vascular 
  Low-risk surgeries
9 (9.1)
43 (43.4)
0 (0.0)
0 (0.0)
1 (1.0)
0 (0.0)
0 (0.0)
46 (46.5)
14 (28.0)
9 (18.0)
1 (2.0)
9 (18.0)
1 (2.0)
2 (4.0)
1 (2.0)
14 (28.0)
0 (0.0)
6 (5.9)
0 (0.0)
54 (53.5)
10 (9.9)
20 (19.8)
0 (0.0)
11 (10.9)
9 (8.1)
24 (21.6)
13 (11.7)
14 (12.6)
4 (3.6)
2 (1.8)
1 (0.9)
52 (46.8)
4 (5.6)
21 (29.6)
2 (2.8)
15 (21.1)
2 (2.8)
3 (4.2)
7 (9.9)
18 (25.4)
36 (8.3)
103 (23.8)
16 (3.7)
92 (21.3)
18 (4.2)
27 (6.3)
9 (2.1)
141 (32.6)
Timing of surgery, n (%)
    < 24 hours after acute event
    24–72 hours after acute event
    Other
3 (3.0)
14 (14.1)
82 (82.8)
4 (8.0)
11 (22.0)
35 (70.0)
0 (0.0)
0 (0.0)
101 (100)
12 (10.8)
21 (18.9)
78 (70.3)
2 (2.8)
4 (5.6)
65 (91.6)
21 (4.9)
50 (11.6)
361 (83.5)
History of coronary artery disease, n (%) 20 (20.2) 5 (10.0) 12 (11.9) 15 (13.5) 9 (12.7) 61 (14.1)
History of peripheral vascular disease, n (%) 2 (2.0) 5 (10.0) 8 (7.9) 1 (0.9) 7 (9.9) 23 (5.3)
History of cerebrovascular event, n (%) 6 (6.1) 3 (6.0) 2 (2.0) 10 (9.0) 4 (5.6) 25 (5.8)
History of congestive heart failure, n (%) 4 (4.0) 0 (0.0) 0 (0.0) 1 (0.9) 2 (2.8) 7 (1.6)
Use of insulin or an oral hypoglycemic, n (%) 13 (13.1) 2 (4.0) 7 (6.9) 12 (10.8) 14 (19.7) 48 (11.1)
Hypertension, n (%) 36 (36.4) 15 (30.0) 44 (43.6) 46 (41.4) 43 (60.6) 184 (42.6)
Smoking status, n (%)
 Never
 Current
 Former
68 (68.7)
15 (15.1)
16 (16.2)
23 (46.0)
4 (8.0)
23 (46.0)
39 (38.6)
30 (29.7)
32 (31.7)
77 (69.4)
15 (13.5)
19 (17.1)
31 (43.7)
15 (21.1)
25 (35.2)
238 (55.2)
78 (18.2)
115 (26.6)
Serum creatinine >1175 μmol/L, n (%) 0 (0.0) 2 (4.0) 1 (1.0) 4 (3.6) 5 (7.0) 12 (2.8)
* Low-risk surgeries include:  parathyroid, thyroid, breast, hernia, local anorectal procedure, oopherectomy, salpingectomy, endometrial ablation, 
peripheral nerve surgery, ophthalmology, ears/nose/throat surgery, vertebral disc surgery, spinal fusion, hand surgery, cosmetic surgery, arterio-venous 
access surgery for dialysis, other surgeries.Open Medicine 2011;5(4)e198
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Table 3 reports the observed major vascular event 
rates and the expected major vascular event rates ac-
cording to the RCRI. Observed event rates were 6 fold 
higher (99% CI 3.5–9.7) than the expected event rates 
according to the RCRI.
3 
The median number of protocol troponin assays meas-
ured (maximum of 4 per patient) was 4.0 (IQR 3.0–4.0) 
per patient. Of the 18 patients who suffered a myocar-
dial infarction, 12 (66.7%) had no ischemic symptoms to 
suggest myocardial infarction, but all had another defin-
ing feature of myocardial infarction (e.g., ischemic ECG 
changes). Therefore, probably 12 (66.7%) of these myo-
cardial infarctions would have gone undetected without 
perioperative troponin monitoring. 
 
Table 3:  Observed and expected event rates (according to the Revised Cardiac Risk Index) by number of risk factors
Number of
risk factors†
Number 
of patients
Observed
 events‡
Observed
event rate
Expected 
event rate§
Expected
 events
Ratio of observed 
to expected events 
(99% CI*)
Canada 0 41 0 0% 0.4% 0.18 0  (0 –28.8)
1 39 3 7.7% 1.0% 0.37 8.0 (0.9–29.4)
2 12 2 16.7% 2.4% 0.28 7.1 (0.4–32.8)
≥ 3 7 3 42.9% 5.3% 0.37 8.0 (0.9–29.3)
All 99 8 8.1% 1.2% 1.21 6.6  (2.1–15.3)
Colombia 0 30 1 3.3% 0.4% 0.13 7.4 (0.04–55.2)
1 18 3 16.7% 1.0% 0.17 17.4 (2.0–63.8)
2 1 0 0% 2.4% 0.02 0 (0–224.9)
≥ 3 1 0 0% 5.3% 0.05 0 (0–99.1)
All 50 4 8.0% 0.8% 0.38 10.4 (1.8–32.8)
Italy 0 64 2 3.1% 0.4% 0.29 7.0 (0.4–32.3)
1 28 1 3.6% 1.0% 0.27 3.7 (0.02–27.7)
2 7 0 0% 2.4% 0.16  0 (0–32.1)
≥ 3 2 0 0% 5.3% 0.11 0(0–49.6)
All 101 3 3.0% 0.8% 0.83 3.6 (0.4–13.3)
Hong 
Kong
0 62 2 3.2% 0.4% 0.28 7.2 (0.4–33.3)
1 36 4 11.1% 1.0% 0.34 11.6 (2.0–36.6)
2 6 0 0% 2.4% 0.14 0 (0–37.5)
≥ 3 7 3 42.9% 5.3% 0.37 8.0 (0.9–29.3)
All 111 9 8.1% 1.0% 1.14 7.9 (2.8–17.6)
Brazil 0 29 0 0% 0.4% 0.13 0  (0–40.7)
1 25 1 4.0% 1.0% 0.24 4.2 (0.02–31.1)
2 12 0 0% 2.4% 0.28 0 (0–18.7)
≥ 3 5 2 40.0% 5.3% 0.27 7.5 (0.4–34.7)
All 71 3 4.2% 1.3% 0.92 3.3 (0.4–11.9)
Total 0 226 5 2.2% 0.4% 1.01 4.9 (1.1–13.9)
1 146 12 8.2% 1.0% 1.40 8.6 (3.5–17.3)
2 38 2 5.3% 2.4% 0.90 2.2 (0.1–10.4)
≥ 3 22 8 36.4% 5.3% 1.18 6.8 (2.2–15.8)
All 432 27 6.3% 1.0% 4.48 6.0 (3.5–9.7)
†  Risk factors = ischemic heart disease, cerebrovascular event, congestive heart failure, diabetes, creatinine > 175 μmol/L, and high risk surgery (i.e., vascular, intra-
peritoneal, or intrathoracic)
‡  Events = cardiovascular death, nonfatal myocardial infarction, nonfatal cardiac arrest, or nonfatal stroke
 § Expected event rates = rates based on the Revised Cardiac Risk Index3
* CI = confi  dence intervalOpen Medicine 2011;5(4)e199
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surgery requiring hospital admission.
3 This study sug-
gests that major perioperative vascular events occur in 
1.4% (95% CI 1.0–1.8%) of adults.
3 
Several potential explanations exist for the higher 
event rate (i.e., 6.3%) in the VISION Pilot Study. First, 
the patient population may have changed in the time 
(i.e., > a decade) between the study by Lee et al. and our 
study. Since then patients with coronary artery disease 
are living longer and developing conditions that require 
noncardiac surgery, and a higher proportion of elderly 
patients are now undergoing noncardiac surgery, rais-
ing  questions  regarding  the  applicability  of  Lee  and 
colleagues results from the late 1980s and early 1990s. 
Second, we used troponin T whereas Lee and colleagues 
used CK-MB in the diagnostic criteria for myocardial 
infarction. CK-MB is prone to false-positive and false-
negative values for perioperative myocardial infarction.
5 
Third, we included emergent surgical cases (8 events oc-
curred in emergent patients), and we considered stroke 
a major adverse outcome whereas the study by Lee and 
colleagues excluded emergent surgical cases, and stroke 
was not considered as a major vascular event.
7 Our study 
included data from 5 hospitals in 5 countries, whereas 
the study by Lee and colleagues included patients from 
a single hospital. Finally, our results may represent a 
chance finding as a consequence of the small sample size. 
We are unaware of any prior studies that have com-
pared observed event rates to the expected event rates 
according to the RCRI. Several prior studies have dem-
onstrated  similar  results  to  our  current  finding  that 
most patients suffering a perioperative myocardial in-
farction do not experience ischemic symptoms. Three 
small prospective cohort studies
10–12 of patients under-
going various noncardiac surgeries who had at least 1 
postoperative measurement of a cardiac enzyme or bio-
marker suggested that approximately half (45%, 95% CI 
29–62%) of the patients who suffered a perioperative 
myocardial infarction had no ischemic symptoms to 
suggest myocardial infarction.
5 One large international 
study that evaluated 415 perioperative myocardial in-
farctions demonstrated that 65.3% of these patients 
did not experience ischemic symptoms, and patients 
suffering an asymptomatic perioperative myocardi-
al infarction had equally poor prognoses as patients 
suffering a perioperative myocardial infarction with is-
chemic symptoms.
6 The findings from these studies and 
the VISION Pilot Study provide consistent and strong 
evidence that monitoring troponin measurements after 
surgery will allow physicians to avoid missing the ma-
jority of patients suffering a perioperative myocardial 
infarction.
Discussion
Principal  findings. Among patients >  45 years of age 
undergoing noncardiac surgery requiring hospital ad-
mission,  we  demonstrated  a  6.3%  (99%  CI  3.9–10.0) 
event rate for major vascular events during the first 30 
days after surgery. In our study, the RCRI substantially 
underestimated the risk of major perioperative vascular 
events. Physicians probably would have missed a major-
ity (i.e., 66.7%) of perioperative myocardial infarctions 
if we had not monitored troponin measurements during 
the first few days after surgery. 
Strengths and weaknesses of the study. Strengths of 
our study include its reflection of current practice across 
multiple international hospital sites (with representation 
from North America, South America, Europe, and Asia).   
Research personnel used a wide variety of approaches 
to identify eligible patients (e.g., screening patient lists 
in the preoperative assessment clinic, surgical wards, 
intensive care units, and preoperative holding area). We 
included patients who underwent urgent/emergent sur-
gery, and patients who underwent surgery on weekends. 
Two independent outcome adjudicators, blinded to pa-
tients’ vascular risk factors, evaluated all major vascu-
lar events, and we used a consensus process to resolve 
disagreements. We achieved 99.3% follow-up at 30 days 
after surgery. 
Our study has several limitations. We enrolled only 
432 patients and observed only 27 major vascular 
events; therefore, the findings of this pilot study war-
rant cautious interpretation. We evaluated the accuracy 
of the RCRI but were unable to conduct similar analy-
ses according to other risk indices (e.g., Veterans Affairs 
Model, Modified Cardiac Risk Index)
8,9 because the ori-
ginal publications did not report the precision of their 
estimates. Using the data from the original RCRI Study, 
we previously reported the expected incidence of major 
perioperative cardiac events (i.e., cardiac death, nonfatal 
myocardial infarction, and nonfatal cardiac arrest) ac-
cording to the RCRI Score.
3 In the VISION Pilot Study 
our primary outcome also included fatal and nonfatal 
stroke. This increased our observed event rate; however, 
this accounts only for a small portion (i.e., 2 events) of 
the difference between our observed event rate (i.e., 27 
events) and our expected event rate (i.e., 4.5 events), 
Table 3. 
Our study in relation to other studies. Considering 
prior  research,  the  study  by  Lee  and  colleagues
7 pro-
vides the best estimate of the incidence of major vascu-
lar events in unselected adults undergoing noncardiac Open Medicine 2011;5(4)e200
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On the basis of the results of the VISION Pilot Study 
we have initiated the full-scale large international   
VISION Study. This study is designed to ensure adequate 
power (i.e., we aim to have at least 720 major vascular 
events) to allow us to determine the optimal clinical 
risk estimation model for predicting major periopera-
tive vascular events and myocardial infarction. A model 
establishing risk groups for perioperative myocardial 
infarction will allow us to determine the cost to avoid 
missing a myocardial infarction across risk groups, and 
this will allow physicians and funders to decide what pa-
tient groups they want to target for monitoring troponin 
measurements after surgery. An accurate risk estimation 
model for major perioperative vascular complications is 
essential to facilitate informed patient and physician 
decision-making regarding the appropriateness of non-
cardiac surgery. Further, such a model has the potential 
to improve patient outcomes through the identification 
of high-risk patients who may benefit from prophylactic 
measures (e.g., a statin) and enhanced monitoring after 
surgery (e.g., telemetry unit).
2
 
conclusions
Our  results  suggest  that  major  perioperative  vascular 
events are more common than previously reported, that 
the RCRI underestimates risk, and that monitoring tro-
ponins after surgery will allow physicians to avoid mis-
sing myocardial infarction. Results from the ongoing 
VISION Study will further inform these issues. 
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